Cipla surges to record high on earnings
Reuters Market Eye - Shares in Cipla (CIPL.NS) gain as much as 4.06 percent to a record high after the drug maker reported a bigger-than-expected 62 percent surge in July-September net profit.
Despite the surge in share prices, Citigroup says on Tuesday it remains cautious, saying the earnings surprise were mainly driven by the generic version of anti-depressant drug Lexapro, whose exclusivity would tail off in the second half of the fiscal year.
Cipla had earlier given a revenue guidance of up to 12 percent for the current fiscal year, but Citigroup says the company management has now revised its topline growth to 15 percent or above in FY13.
Citigroup adds positives such as better product mix and upside from a weaker rupee appeared factored into estimates and valuations.
The bank raised its target price to 390 rupees from 360 rupees, but retained its 'neutral' rating.
- Tweet this
- Share this
- Digg this
The World Trade Organization failed on Thursday to reach a deal to standardise customs rules, which would have been the first global trade reform in two decades but was blocked by India's demands for concessions on agricultural stockpiling. Full Article
China PMIs jump to multi-month highs in July, add to view economy is steadying Full Article